Last reviewed · How we verify
UMECLIDINIUM BROMIDE
At a glance
| Generic name | UMECLIDINIUM BROMIDE |
|---|---|
| Modality | Small molecule |
| Phase | FDA-approved |
| First approval | 2013 |
Approved indications
Common side effects
- Upper respiratory tract infection
- Headache
- Back pain
- Pneumonia
- Bronchitis
- Oral candidiasis
- Arthralgia
- Influenza
- Sinusitis
- Pharyngitis
- Rhinitis
- Constipation
Key clinical trials
- Pragmatic Open - Label Randomized Clinical Trial of FF/UMEC/VI vs Non-ellipta Usual Care ICS-LABA for Adult Participants With Uncontrolled Asthma (PHASE4)
- Immuno-inflammatory Response of Erdosteine in COPD (NA)
- To Evaluate Real-World Effectiveness of Fluticasone Furoate/Umeclidinium Bromide/Vilanterol (FF/UMEC/VI) in a Single Inhaler (Trelegy Ellipta) in Participants With Symptomatic COPD (PHASE4)
- ANTES B+ Clinical Trial (PHASE4)
- Acupuncture for Persistent Dyspnea Despite Medical Treatment in COPD (NA)
- A Study Using US Medical and Pharmacy Claim Records to Compare the Resource Use, Cost, and Outcomes of People With COPD Who Take Either Tiotropium + Olodaterol or Fluticasone + Umeclidinium + Vilanterol
- A Study in the US Based on Pharmacy and Medical Claims That Compares How Well Stiolto® and Trelegy® Work in People With Chronic Obstructive Pulmonary Disease (COPD)
- Dose-range Finding Efficacy and Safety Study for QBW251 in COPD Patients (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- UMECLIDINIUM BROMIDE CI brief — competitive landscape report
- UMECLIDINIUM BROMIDE updates RSS · CI watch RSS